Cleara Biotech B.V.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cleara Biotech B.V. - overview
Established
2018
Location
Utrecht, -, Netherlands
Primary Industry
Biotechnology
About
Based in the Netherlands, and founded in 2018, Cleara Biotech B. V. provides therapies for the treatment of different types of “senescent” cells. The company was spun out from the Medical Center Utrecht (UMCU).
In September 2022, the firm raised USD 2. 5 million in Seed funding led by investor Apollo Health Ventures with participation from other investors Curie Capital, Longevity Tech Fund, and ROM Utrecht Region. The company develops the next generation of subtype-specific anti-senescence compounds which helps in restoring tissue homeostasis. Additionally, the firm offers a FOXO4-based treatment approach that uses the biomarker and eliminates the biomarker-positive scarred cells.
It develops the technology against scarred cellular senescence which helps in the treatment of metastatic, mutant-p53 cancer. The company plans to use the September 2022 funding to progress the company compounds toward clinical development and further build its developmental pipeline and management team.
Current Investors
Apollo Health Ventures, Curie Capital, Longevity Tech Fund
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.clearabiotech.com
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.